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Abstract: An unusual polyketide with a new carbon skeleton, lindgomycin (1), and the 
recently described ascosetin (2) were extracted from mycelia and culture broth of different 
Lindgomycetaceae strains, which were isolated from a sponge of the Kiel Fjord in the Baltic Sea 
(Germany) and from the Antarctic. Their structures were established by spectroscopic means.  
In the new polyketide, two distinct domains, a bicyclic hydrocarbon and a tetramic acid,  
are connected by a bridging carbonyl. The tetramic acid substructure of compound 1  
was proved to possess a unique 5-benzylpyrrolidine-2,4-dione unit. The combination of  
5-benzylpyrrolidine-2,4-dione of compound 1 in its tetramic acid half and 3-methylbut-3-
enoic acid pendant in its decalin half allow the assignment of a new carbon skeleton. The 
new compound 1 and ascosetin showed antibiotic activities with IC50 value of 5.1 (±0.2) µM 
and 3.2 (±0.4) μM, respectively, against methicillin-resistant Staphylococcus aureus. 
Keywords: marine fungi; lindgomycin; antibiotic; MRSA; marine natural products 
 
1. Introduction 
Marine-derived fungi living in a stressful habitat are of great interest as new, promising sources of 
biologically active products. Since marine organisms live in a biologically competitive environment with 
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unique conditions of pH, temperature, pressure, oxygen, light, nutrients, and salinity, the chemical 
diversity of the secondary metabolites from marine fungi is considerably high [1–7]. Various new genera 
were described from marine resources, however, marine isolates of known taxa reveal to be potent producers 
of novel chemistry as well. The fungal family Lindgomycetaceae (Pleosporales, Dothideomycetes) was 
introduced by Hirayama et al. [8] to accommodate four new species of the genus Lindgomyces. Another 
three Lindgomyces species were added by Raja et al. [9,10], and these authors also included 
Massariosphaeria typhicola, a closely related species, into the Lindgomycetaceae. Later on, the newly 
isolated species Lolia aquatica was added [11] and Clohesiomyces aquaticus was shown to belong to 
this family according to sequence data [12]. All members of the Lindgomycetaceae were isolated from 
submerged parts of decaying wood and plant material in a freshwater environment. Little is known on 
their metabolic capabilities and on their production of bioactive compounds. The only available data are 
from Raja et al. [10], who found a fatty acid, 6E,9E-octodecadienoic acid, and ergosterol peroxide as 
the major chemical compounds in Lindgomyces angustiascus.  
The naturally occurring pyrrolidine-2,4-dione (tetramic acid) derivatives originating from a variety 
of marine and terrestrial species have attracted a great deal of interest due to their broad-spectrum 
biological activities and challenging structural complexity [13,14]. The majority of the compounds 
isolated to date exhibited antibiotic or antiviral activity. Tetramic acids possessing an octahydronaphthalene 
skeleton are rare in nature, showing activity against Gram-positive bacteria [13]. Recently, ascosetin was 
described as a new antibacterial tetramic acid derivative [15]. 
In this study, two marine strains of the family Lindgomycetaceae were shown to exhibit a diverse 
chemical profile, including tetramic acid derivatives having novel structures. The strains were isolated from 
a sponge of the Baltic Sea (Kiel Fjord) and from the Antarctic. The new compound lindgomycin (1) and 
ascosetin (2) showed antibiotic activities against human and plant pathogenic microorganisms. 
2. Results and Discussion 
2.1. Identification of Strains KF970 and LF327 
Two fungal isolates, strains KF970 and LF327, which are members of the family Lindgomycetaceae, 
were isolated from different marine habitats. Both strains grew only as sterile mycelium on the media 
used, but did not produce conidia or ascomata on ten different media, e.g., on WSP30 (Figure 1). Thus, 
morphological criteria for identification of the strain were lacking. The sequences of the 18S rRNA 
genes comprised 1546 nucleotides for KF970 and 1065 nucleotides for LF327, respectively. Both 
sequences exhibited a similarity of 99.7% to each other. The highest sequence similarity (100%) was 
observed for the 18S RNA gene sequence to “Phyllosticta” flevolandica AFTOL-ID 1786. Nevertheless, 
the deposited sequence of the P. flevolandica strain comprises only approximately a fourth of the length 
of 18S rRNA gene (441 nucleotides) and Crous et al. [16] have shown that “Phyllosticta” flevolandica 
does not affiliate with all members of the genus Phyllosticta, which belong to the Botryosphaeriales. 
Therefore, the strains most closely related were taken into consideration for the phylogenetic classification. 
Among these, Massariosphaeria typhicola CBS 609.86 (acc. no. KF314118) showed similarities of 
99.9% to KF970 and 99.5% to LF327, respectively. The 18S rDNA sequences of strains KF970 and 
LF327 showed 99.2%–99.5% and 99.0%–99.2% similarity to the type of strains of the seven known 
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Lindgomyces species [10]. Clohesyomyces aquaticus MFLUCC11-0092 (acc. no. JX276949) was 99.0% 
similar to KF970 and 99.78% similar to LF327. A comparison with the genus Lolia was not possible 
because no 18S rRNA gene sequence was deposited. 
In addition, the 28S rRNA gene fragment was analysed. The sequences had a length of 820 
nucleotides (KF970) and 819 nucleotides (LF327) and showed a similarity of 99.1% to each other.  
The closest relative on the basis of the 28S rRNA gene sequences were C. aquaticus and M. typhicola.  
C. aquaticus MFLUCC11-0092 (acc. no. JX276950) exhibited a similarity of 98.9% (KF970)  
and 98.8% (LF327). M. typhicola CBS 609.86 (acc. no. EF165033) showed a similarity of 98.6% and 
99.0% for KF970 and LF327, respectively. The comparison of strains KF970 and LF327 with Lolia 
aquatica (acc. no. HM367732) revealed 98.1% and 98.2% sequence similarities, respectively. Members of 
the genus Lindgomyces bore resemblance in the range of 97.3%–98.4% (KF970) and 97.4%–98.2% (LF327).  
On the basis of the phylogenetic analyses, KF970 and LF327 were clearly assigned to the family 
Lindgomycetaceae (Pleosporales, Dothideomycetes). 
 
Figure 1. Lindgomycetaceae strain KF970, agar colony on WSP30 medium after 21 days of 
incubation at 22 °C. 
2.2. Metabolic Profiles of the Strains KF970 and LF327 
Interestingly, both Lindgomycetaceae strains, which originated from different geographic regions, 
produced compounds 1 and 2. Cultivation experiments of LF327 were carried in two different media 
under static and non-static conditions. Mycelium and culture broth were not separated. Compounds 1 
and 2 were produced in GYM4 medium. The comparison of static and non-static cultures showed that 
the production level in static cultures was much higher. The evaluation was done by the comparison of 
UV spectra and ESIMS data, obtained by analysing the extract by analytical HPLC-UV/MS. 
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2.3. Structural Elucidation 
The MeOH extracts of the mycelia and the broth of strain KF970 were subjected to repeated column 
chromatography to purify the two polyketides 1 and 2 (Figure 2).  
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Figure 2. Structures of compounds 1 and 2.  
Compound 1 was isolated as a white powder. The molecular formula was determined to be C29H35NO5 
by analysis of the HR-TOF-MS ion peak at m/z 478.2603 [M + H]+ (calcd. 478.2588). The formula was 
supported by the 13C NMR data, which showed 13 unsaturated degrees. The proton signal of H-5 
appeared as a broad singlet. No observation of coupling of H-5 and H-5 indicated that the dihedral angle 
between H-5 and H-5 was around 90°. The NMR data (Table 1) in the upfield region of 1 were similar 
to those of the phomasetin and equisetin analogues [17]. These molecules contain two distinct  
domains, a bicyclic hydrocarbon and a tetramic acid, connected by a bridging carbonyl [13–15,17–19].  
The 13C NMR spectrum showed the presence of 18 signals for the hydrocarbon domain including a 
decahydronaphthalene basic skeleton and a sec-butyl moiety, with the remaining 11 resonances 
corresponding to a heterocyclic domain including a tetramic acid basic skeleton and a benzyl moiety. 
When compared to the NMR data of the polyketide phomasetin, isolated from the fungus Fusarium 
heterosporum, compound 1 showed similar chemical shifts of the main decalin skeleton. However, the 
structures of the tetramic acid and attached unit at the decahydronaphthalene ring were less similar  
to phomasetin.  
Table 1. NMR data (500 MHz) for compounds 1 and 2 in CD3OD. 
Position 
1 2 
δC a,b, Mult. δH c, Mult. (J in Hz) δC a,b, Mult. δH c, Mult. (J in Hz) 
1 201.4, C  202.3, C  
2 52.2, C  52.7, C  
3α 58.0, CH 3.46, s 57.9, CH 3.52, s 
4 130.8, C  130.9, C  
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Table 1. Cont. 
5 129.5, CH 5.41, br s 129.6, CH 5.43, br s 
6α 39.9, CH 1.88, m 39.8, CH 1.90, m 
7α 43.7, CH2 1.87, m 43.8, CH2 1.88, m 
7β  0.90, m  0.86, m 
8α 34.8, CH 1.54, m 34.8, CH 1.56, m 
9α 37.1, CH2 1.73, m 37.1, CH2 1.67, m 
9β  1.05, m  1.06, m 
10α 29.6, CH2 0.95, m 29.6, CH2 1.07, m 
10β  1.71, m  1.76, m 
11β 41.6, CH 1.81, m 41.8, CH 1.87, m 
12 15.6, CH3 1.38, s 15.6, CH3 1.49, s 
13 159.8, C  159.9, C  
14 121.5, CH 5.63, s 121.6, CH 5.66, s 
15 169.6, C  169.6, C  
16 17.3, CH3 1.91, s 17.2, CH3 1.97, s 
17 22.9, CH3 0.93, d (J = 6.5) 22.9, CH3 0.92, d (J = 6.5) 
18 22.9, CH3 1.54, s 22.8, CH3 1.55, s 
2′ 173.0, C  173.0, C  
3′ n.d.  n.d.  
4′ 194.1, C  195.8, C  
5′ 62.2, CH 4.07, dd (J = 6.5, 4.3) 60.4, CH 3.90, m 
6′a 38.5, CH2 3.09 dd (J = 13.9, 4.3) 42.4, CH2 1.85, m 
6′b  2.96 dd (J = 13.9 6.5)  0.90, m 
7′ 136.9, C  22.1, CH 1.50, m 
8′ 130.8, CH 7.19, d (J = 8.0) 23.9, CH3 0.97, d (J = 6.8) 
9′ 129.3, CH 7.24, t (J = 8.0) 22.89, CH3 0,95, d (J = 6.8) 
10′ 127.9, CH 7.21, t (J = 8.0)   
11′ 129.3, CH 7.24, t (J = 8.0)   
12′ 130.8, CH 7.19, d (J = 8.0)   
a Recorded at 125 MHz; b Multiplicities inferred from DEPT and HMQC experiments; c Recorded at 500 MHz. 
The 18 signals for the hydrocarbon domain comprised four methyls (δC 15.6, 17.3, 22.9, and 22.9), 
three methylenes (δC 43.7, 37.1, and 29.6), four methines (δC 58.0, 39.9, 41.6, and 34.8), a quaternary carbon 
(δC 52.2), two sets of double bonds (130.8, 129.5, 159.8, and 121.5), a carboxylic carbon (δC 169.6), and enol 
carbon (δC 201.4). In the COSY spectrum of 1 (Figure 3), the methine proton at δH 1.88 (m, H-6) was 
coupled with another methine proton at δH 1.81 (m, H-11), the methylene protons at δH 1.87 (m, H-7α) and 
0.90 (m, H-7β), and the olefin proton at 5.41, (br s, H-5). The methine proton at δH 1.54 (m, H-8) exhibited 
cross peaks with methylene protons of H2-7, H2-9, and methyl protons at δH 0.93 (d, J = 6.5 Hz, Me-17) in 
the COSY spectrum of 1. The sequence of a six-member ring system of H-6/H2-7/H-8/H2-9/H2-10/H-11 with 
Me at C-8 was deduced from the above 1H–1H COSY analyses (Figure 3). HMBC analyses complete the 
formation of the decalin skeleton with a characteristic sec-butyl pedant (Figure 3). HMBC cross peaks 
of Me-17/C-7 and Me-17/C-9 confirmed the position of methyl group at C-8 of ring A. In the 1H NMR 
spectrum of 1, two methyl groups displayed two singlet signals, one of which was assigned at quaternary 
C-2 from the observation of HMBC cross peaks of Me-12/C-1 and Me-12/C-2. The long range 
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correlations from the proton at δH 1.54 (s, Me-18) to the double bond carbon signals at δC 130.8 (s, C-4) 
and δC 129.5 (d, C-5) positioned the remaining methyl at C-4. The pendant attached at C-3 was obviously 
different from the known phomasetin. Instead of being a penta-diene, a 3-methylbut-3-enoic acid unit 
was attached at C-3. The carboxylic carbon at δC 169.6 (s) was attributed to C-15 from the observation 
of long range correlations from the proton signals at δH 5.63 (s, H-14) to carboxylic C-15. The methyl 
group in the pendant was assigned at C-13 from analysis of the HMBC cross peaks from Me-16 to 
olefinic C-13 and C-14. The substructure of the pedant was deduced to be a 3-methylbut-3-enoic acid 
unit, which was positioned at C-3 from the observation of HMBC correlation from the proton at δH 3.46 
(s, H-3) to the carbon at δC 159.8 (s, C-13) and HMBC correlations from the Me proton at δH 1.91  
(s, Me-16) and olefinic proton at δH 5.63 (s, H-14) to the carbon signal at δC 58.0 (C-3). The  
two-dimensional NMR analyses mentioned above permitted the assignment of the bicyclic hydrocarbon 
unit of 1. 
O
OH
HN
O
O
O
H
1
1H 1H COSY HMBC from H to C  
Figure 3. Key 1H–1H COSY and HMBC correlations of compound 1. 
The formula indicated that 11 resonances remained to be assigned to the tetramic acid half of molecule 1, 
corresponding to a tetramic acid basic skeleton and a benzyl moiety. However, the C-3′ signal was not 
detected due to rapid tautomerisations to multiple enol forms [18]. In the downfield region of the NMR 
spectra of 1, two sets of equivalent aromatic protons at δH 7.19, (d, J = 8.0 Hz, H-8′/12′) and 7.24  
(t, J = 8.0 Hz, H-9′/11′) and an aromatic triplet at δH 7.21 (t, J = 8.0 Hz, H-10′) indicate that a single 
substituted benzene ring unit was added in the core structure of a tetramic acid moiety coupling with a 
decalin moiety. The structure of the five-member lactam ring at the tetramic acid unit was approved by 
the HMBC cross peaks of H-5′/C-2′. The five-member lactam ring proved to be linked at the quaternary 
C-2 via the oxygenated enolic C-1 from the observation of long range correlation from the proton signal 
at δH 1.38 (s, Me-12) to the enolic carbon signal at δC 201.4 (s, C-1). Owing to the formation of the 
intermolecular hydrogen bond between the hydroxyl at the olefin carbon and the carbonyl at the lactam 
ring, the C-1 was highly downshifted [14,17,19]. The benzylic methylene of H2-6′ showed long range 
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two-dimensional 1H–13C correlations to the aromatic carbon C-8′/12′ and C-7′ of the phenyl ring and to 
the carbonyl C-4′ of the pyrrolone ring. This indicated that the benzene unit was linked with the five-member 
lactam unit via a methene bridge. This inference was confirmed by the observation of 1H–1H COSY 
cross peaks of H2-6′/H-5′. Thus, the planar structure of 1 was elucidated as shown in Figure 2.  
The 1,3-diaxial NOESY cross peaks of H-6α/H-8α, H-8α/H-10α, H-11β/H-7β, and H-11β/H-9β 
revealed a 6,11-trans ring fusion between the cylcohexyl chair and cyclohexenyl boat rings of the 
bicyclic decalin with a β-oriented Me at C-8 (Figure 4). The NOESY correlations from Me-12 to the axial 
H-6a and H-3 indicated a β-oriented 3-methylbut-3-enoic acid pendant at C-3 and a β-oriented tetramic 
acid pendant at C-2. The diagnostic NOESY correlation from the olefinic proton at δH 5.63 (s, H-14) to 
the proton at δH 3.46 s (s, H-3) revealed that the stereochemistry of the double bond between C-13 and 
C-14 was in an E configuration. Thus, compound 1 is found to be an unusual polyketide and is given the 
trivial name lindgomycin. The combination of 5-benzylpyrrolidine-2,4-dione of compound 1 in its 
tetramic acid half and the 3-methylbut-3-enoic acid pendant in its decalin half allowed the assignment 
of a new carbon skeleton.  
 
Figure 4. Key NOESY correlations of compound 1. 
Compound 2 was identified as the recently described ascosetin by comparison of spectroscopic data 
reported by Ondeyka et al. [15].  
2.4. Biological Activities 
Both lindgomycin (1) and ascosetin (2) exhibited strong antibiotic activities with IC50 values in the 
range of 2 to 18 µM (Table 2). The effects against the clinically relevant bacteria Staphylococcus 
epidermidis, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Propionibacterium 
acnes were two times less in comparison with chloramphenicol. The activity against the human 
pathogenic yeast Candida albicans was four times lower than it was observed for nystatin. The causative 
agents of black rot in crucifers (e.g., cabbage) and of leaf spot disease on crops (e.g., wheat), 
Xanthomonas campestris and Septoria tritici, were also inhibited by the new compounds. No inhibition 
of Gram-negative bacteria was observed.  
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Table 2. Antibiotic profiles of compounds 1 and 2. The IC50 values are given in µM. 
Test Strain 1 2 Positive Controls 
B. subtilis 2.2 (±0.6) 3.4 (±1.1) chloramphenicol: 1.45 (±0.13) 
X. campestris 17.8 (±1.6) 14.8 (±0.7) chloramphenicol: 2.88 (±0.9) 
S. epidermidis 4.6 (±0.8) 6.3 (±0.7) chloramphenicol: 1.81 (±0.04) 
S. aureus 2.7 (±0.56) 2.9 (±1.1) chloramphenicol: 1.59 (±0.07) 
S. aureus (MRSA) 5.1 (±0.2) 3.2 (±0.4) chloramphenicol: 2.46 (±0.04) 
C. albicans 5.7 (±0.9) 8.0 (±1.4) nystatin: 1.71 (±0.28) 
S. tritici 5.1 (±0.7) 10.0 (±3.1) nystatin: 0.76 (±0.23) 
P. acnes 4.7 (±0.4) 2.8 (±0.7) chloramphenicol: 1.01 (±0.01) 
E. coli >100  >100 chloramphenicol: 373 (±0.10) 
P. aeruginosa >200 >200 chloramphenicol: 8.86 (±0.36) 
2.5. Biotechnological Scale Up 
In order to insure sustainable production of 1 and 2 in larger amounts, we have performed experiments 
to optimise and scale up the biotechnological production from Erlenmeyer flask cultures to controllable 
stirred tank reactors. As other fungi, strain KF970 showed variation in the metabolite production in 
various media and growth conditions. Among a number of culture media, the best production of 1 and 2 
was found in GYM4 medium and in standing cultures as well as in shaken Erlenmeyer flasks at pH 7.2 
and in the absence of added salt to the medium.  
Interestingly, the culture medium and the age of the pre-cultures were highly important for good 
growth and production. GYM4 was the best medium for the pre-cultures, but if these were older than  
21 days, no significant production could be obtained. 
Based on the content of nitrogen in the candidate structures, a medium containing a high 
nitrogen/carbon ratio was introduced in order to further improve the production rate. Casamino acids 
medium proved to support very good growth in small brown pellets and improvement of the production 
(compared to GYM4) of 2–4 times. This was observed in standing cultures but more pronounced in 
shaken Erlenmeyer flasks. 
For a sustainable large scale production, the transfer of the production into a fermenter system  
(stirred tank reactor) is essential. Therefore, the best conditions for the production of 1 and 2 by strain 
KF970 in Erlenmeyer flasks were used to establish the production in a 10 L fermenter. Low pH turned 
out to be best for production of secondary metabolites by strain KF970, and for all subsequent experiments 
in STR, the pH value was set to pH 5. The fungus showed comparable growth behavior in a 10 L 
fermenter system with controlled pH and air saturation (minimum value set to 30%), reaching the 
exponential phase of growth after 3 days of cultivation. Both the low pH and stable oxygen levels in the 
medium due to the stirring stimulate hyphal growth. Production of 1 and 2 occurred within the 
exponential growth phase with a maximum after 7 days of cultivation. This is a significant reduction of 
cultivation time for production as compared to a minimum of 14 days needed to reach maximum product 
levels of both compounds in Erlenmeyer flasks. After this period, growth of the fungus continued, but 
concentrations of 1 and 2 slowly decreased (with a half-life of 6 days). Considering the optimal time 
point for harvest, the production yield of 1 and 2 increased from 0.2 mg/L in Erlenmeyer flasks to 5.0 mg/L 
in a 10 L fermenter.  
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3. Experimental Section  
3.1. General Experimental Procedures  
Optical rotations were recorded on a Perkin Elmer 241 polarimeter. The IR spectra were run on a 
Perkin Elmer spectrometer with an attenuated total reflectance (ATR) unit. 1H NMR (500 MHz) and  
13C NMR (125 MHz) spectra were measured at 25 °C on a Bruker AVANCE DMX 500 NMR spectrometer 
with tetramethylsilane (TMS) as internal standard. The signals of the residual solvent protons and the 
solvent carbons were used as internal references (δH 3.31 ppm and δC 49.0 ppm for methanol-d4).  
High-resolution mass spectra were acquired on a benchtop time-of-flight spectrometer (micrOTOF II, 
Bruker Daltonics, Germany) with positive electrospray ionization (ESI). 
3.2. Isolation, Cultivation, and Storage of the Producer Strains KF970 and LF327 
The fungus KF970 was isolated from samples of the expedition of RV Polarstern to the Arctic in 
1991 by K. Schaumann [20]. The strain LF327 was isolated from the sponge Halichondria panicea, 
which was collected at the Kiel Fjord (Baltic Sea, Germany). Both strains were grown on WSP30 agar, 
a modified Wickerham-medium consisting of 1% glucose, 0.5% peptone, 0.3% yeast extract, 0.3% malt 
extract, 3% sodium chloride (pH = 6.8) [21]. The strains were stored in liquid nitrogen and in the 
Microbank System at −80 °C (MAST DIAGNOSTIKA, Reinfeld, Germany). 
3.3. Identification of the Strains KF970 and LF327 
In order to obtain morphological characteristics for the identification of the isolate KF970, it was 
cultivated on the following 10 agar media to stimulate the formation of conidia or ascomata. GPY 
medium: 0.1% glucose × H2O, 0.05% peptone, 0.01% yeast extract, 1.5% agar, North Sea water,  
pH 7.3 ± 0.1; WM medium: 1% glucose × H2O, 0.5% peptone, 0.3% yeast extract, 0.3% malt extract, 
3% sodium chloride, 1.5% agar, pH 6.8; Czapek-Dox medium (Merck, Darmstadt, Germany): 3% sucrose, 
0.3% sodium nitrate, 0.05 magnesium sulfate, 0.05 potassium chloride, 0.001% iron(II)sulfate,  
0.1% di-potassium hydrogen phosphate, 1.5% agar, pH 7.3; ME medium: 1.7% malt extract,  
1.5% sodium chloride, 1.5% agar, pH 4.5; SM medium: 2.0% soja peptone, 1.5% sodium chloride,  
2.0% mannit, 1.5% agar, pH 6.9; PDA medium: 0.4% potato extract, 2.0% glucose × H2O, 1.5% agar, 
pH 4.7; MB medium: 3.74% Bacto Marine Broth (Difco 2216, Becton Dickinson and Company, 
Heidelberg, Germany), 1.5% agar, pH 7.6 ± 0.2; TSB3 + 1% NaCl: 0.3% BD BBL™ Trypticase™ Soy 
Broth (Becton Dickinson and Company, Heidelberg, Germany), 1% NaCl, 1.5% agar, pH 7.2; Carrot 
medium: 100 g grinded carrot, 1.5% agar, pH 6.5. If not otherwise indicated the media were adjusted 
with aqua dest. to 1 L. 
For the genetic characterisation of the fungus the 18S rRNA and 28S rRNA gene sequences  
were analysed. DNA-extraction was performed using the Precellys 24 system (Bertin Technologies, 
Paris, France) according to [22]. Specific PCR for amplification of fungal 18S rRNA and 28S rRNA 
gene fragments was carried out using puReTaq™ Ready-To-Go™ PCR Beads (GE Healthcare,  
Munich, Germany). The PCR of the 18S rDNA sequence was performed using the primers NS1  
(5′-GTAGTCATATGCTTGTCT-3′) and FR1 (5′-AICCATTCAATCGGTAIT-3′) according to  
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Gomes et al. [23]. PCR was conducted as follows: initial denaturation (8 min at 94 °C), 35 cycles of 
primer denaturation (30 s at 94 °C), annealing (45 s at 48 °C), and elongation (3 min at 72 °C), followed 
by a final elongation step (10 min at 72 °C). Since most of the phylogenetic studies which, based on the 
large-subunit RNA, have been performed with the first 800–900 nucleotides, the primers used for the 
amplification of the 28S rDNA fragment (5.8S region, ITS2 and part of the large-subunit RNA) were 
5.8SR (5′-TCGATGAAGAACGCAGCG-3′) and LR7 (5′-TACTACCACCAAGATCT-3′) [24]. The 
conditions for the PCR were: initial denaturation (3 min at 94 °C), 35 cycles of primer denaturation  
(60 s at 94 °C), annealing (30 s at 55 °C), and elongation (2 min at 72 °C) followed by a final elongation 
step (5 min at 72 °C) [25]. The PCR products were checked for correct length, 1650 nucleotides and 
1414 nucleotides, respectively, using a 1% agarose gel in 1× TBE buffer (8.9 mM Tris, 8.9 mM borate, 
0.2 mM EDTA) and the DNA molecular weight marker X (Roche, 0.07–12.2 kbp). PCR products were 
sequenced using the ABI PRISM® BigDye™ Terminator Ready Reaction Kit (Applied Biosystems) on 
an ABI PRISM® 310 Genetic Analyzer (Perkin Elmer Applied Biosystems, Waltham, Massachusetts, USA). 
The sequence of the almost-complete 18S rRNA gene was determined with the primers NS1, 470F  
(5′-CAGCAGGCGCGCAAATTA-3′; Dr. Sven Neulinger, pers. Mitteilung), and FR1. The LR0R  
(5′-ACCCGCTGAACTTAAGC-3′) and LR5 (5′-TCCTGAGGGAAACTTCG-3′) primer were used for 
sequencing the entire 28S rRNA gene fragment [25]. Closest relatives were identified by sequence 
comparison with the NCBI Genbank database using BLAST (Basic Local Alignment Search Tool) [26]. 
Sequence similarity values were determined with the “bl2seq” tool of the NCBI database [27].  
3.4. Comparison of the Metabolic Profiles the Strains KF970 and LF327  
Cultivation of both strains was carried out in two L Erlenmeyer flasks containing 750 mL GYM4  
(0.4% malt extract, 0.4% yeast extract, 0.4% glucose × H2O, 0.2% CaCO3, pH 7.2) for 21 days at 28 °C 
as static and shaken cultures in the dark. Circular agar pieces (WSP30, diameter of 1.8 cm) were used 
for inoculation. Extraction of mycelium and culture broth was performed using ethyl acetate added to 
the cultures in equal volume. The metabolite profiles of both strains were evaluated for compounds 1 
and 2 using analytical HPLC-UV/MS. 
3.5. Fermentation and Production of Extracts for the Purification of Compounds 1 and 2 
Strain KF970 was inoculated onto agar-plates containing WSP30 medium. After incubation for  
15 days at 22 °C the pre-culture was used for inoculation of two L Erlenmeyer flasks containing 750 mL 
SM medium (2% soy peptone, 2% mannitol, 1.5% NaCl, pH 7.0). The flasks were incubated for 32 days 
at 28 °C as static cultures in the dark. The mycelium was separated from the culture medium. The 22 L 
fermentation broth was extracted using ethyl acetate (12 L). After evaporation of the solvents the crude 
extract was re-dissolved in 5 mL methanol and stored at 4 °C until further use.  
3.6. Scale up Production  
For media optimisation, cultures were grown in 100 mL medium (in 300 mL EMK) and inoculated 
with mycelium pieces (2, ø~1 cm). The following media were used: SA (Sabouraud-Agar, 2% glucose, 
1%, pH 5.6), GYM4 (0.4% glucose, 0.4% yeast extract, 0.4% malt extract, 0.2% CaCO3, pH 7.2),  
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Czapek Dox (CD, 3% sucrose, 0.3% sodium nitrate, 0.1% K2HPO4, 0.05% MgSO4, 0.05% KCl,  
0.001% iron(II)sulfate, pH 7.0), WSP30 (1% glucose, 0.5% soy peptone, 0.3% malt extract, 0.3% yeast 
extract, pH 6.6 +/− Tropic marine 3%), ME (1.7% malt extract, 1.5% NaCl), PDA (Potato-Dextrose-
Agar BD (3.9%) or Bouillon (2.65%), pH 5.6), and SM (2% soy peptone, 2% mannitol, 1.5% NaCl,  
pH 6.7). After incubation at 28 °C for 14–24 days, growth and production status were estimated. 
Production was measured using the HPLC-DAD-MS method described above after extraction with a 
minimum of 100 mL ethyl acetate. For optimisation of cultivation time, preculture medium, and 
introduction of casamino acids, the following setups were chosen. (A) cultivation time GYM4 (standing 
and shaken cultures): 6 × 750 mL GYM4 (in a 2 L EMK) were inoculated with 6–8 mycelium pieces  
(ø ~1 cm, 14 days, WSP30), incubation: 28 °C, stand + 120 rpm, 14 days, 21days , 28 days; (B) variation 
of preculture medium: 6 × 750 mL GYM4 (2 L EMK) were inoculated with 6–8 mycelium pieces  
(ø ~1 cm, 14 days, GYM4 or PDA), incubation: 28 °C, stand + 120 rpm, 14 days, 21 days, 28 days;  
(C) casamino acids as medium: 2 × 750 mL casamino acids (in 2 L EMK) were inoculated with  
6–8 mycelium pieces (ø~1 cm, 14 days, WSP30), incubation: 28 °C, stand + 120 rpm, 14 days, 21 days,  
28 days. All cultures were extracted after separation of culture medium and mycelium by addition of 
ethanol (cells) or ethyl acetate (culture supernatant). For subsequent optimisation, GYM4 and casamino 
acid medium (0.25% caseinhydrolysate, 4% glucose, 0.01% MgSO4·7H2O, 0.18% KH2PO4, pH 6.8) were 
used for incubation at 28 °C, 120 rpm or stand, for 15 days. In the 10 L STR system (Biostat, Braun, 
Melsungen, Germany), pH, oxygen, CO2-outlet, and stirring speed were controlled. The oxygen content 
in the medium was set to a minimum of 30% air saturation. Foam formation was stopped by addition of 
antifoam (Sigma, Taufkirchen, Germany). After cultivation, cells were separated from the culture broth 
by means of centrifugation. For the 1 L and 10 L scale, culture supernatant and cells were extracted by 
addition of two volumes ethyl acetate. The organic solvent was separated and concentrated to dryness 
under reduced pressure. 
3.7. Extraction and Isolation of Compounds 1 and 2 
Analytical reversed phase HPLC-DAD(UV)-MS experiments were performed using a C18 column 
(Phenomenex Onyx Monolithic C18, 100 mm × 3.00 mm) applying an H2O/acetonitrile (ACN) gradient 
with 0.1% formic acid added to both solvents (gradient: 0 min 5% ACN, 4 min 60% ACN, 6 min 100% 
ACN; flow 2 mL/min each; 6.1 min 100% ACN, 6.8 min 100% ACN, 7.0 min 5% ACN, 8.2 min 5%; 
flow 2.5 mL/min each) on a VWR Hitachi Elite LaChrom system with an L-2450 diode array detector, 
an L-2130 pump, and an L-2200 autosampler (VWR, Darmstadt, Germany). The system was coupled to 
an ESI-ion trap detector with positive ionization (Esquire 4000, Bruker Daltonics, Germany) for mass 
detection. Compounds 1 and 2 eluted with a retention time of 5.9 min and 6.0 min, respectively.  
The preparative HPLC was conducted with a HPLC-UV system (VWR International LaPrep, pump 
P110, UV detector P311, smartline 3900 autosampler) coupled with a LABOCOL Vario-2000 fraction 
collector (LABOMATIC, Weil am Rhein, Germany) and a C18 column (Phenomenex Gemini-NX C18 
110A, 100 mm × 50 mm). The gradient parameters were: 0 min 10% acetonitrile (ACN), 17.5 min 60% 
ACN, 22 min 100% ACN, 25 min 100% ACN, 26 min 10% ACN, 28 min 10% ACN; flow: 100 mL/min). 
Semi-preparative HPLC was carried out using a HPLC-UV system (VWR Hitachi Elite LaChrom 
system, L-1230 pump, L-2450 diode array detector, L-2200 autosampler, Phenomenex Gemini-NX C18 
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110A, 100 mm × 50 mm, column). For the preparation of compound 1 and 2, ACN was used, with a 
gradient from 65% ACN increasing to 85% in 20 min and 70% ACN increasing to 90% in 20 min, 
respectively, and a flow of 15 mL/min. The compounds eluted with a retention time of 9.1 min and  
8.4 min, respectively. The yield was 8.0 mg of compound 1 and 3.7 mg of compound 2. 
Lindgomycin (1): white powder; [α]D20 −42 (c 0.1, CHCl3); UV (MeOH) λmax (log ε) 254 (4.17),  
293 (4.50) nm; IR νmax 2913, 1630, 1556, 1453, 1378, 1150, 1026, 878, 790, 699, 611 cm−1; 1H NMR 
and 13C NMR, see Table 1; ESIMS m/z 478 [M + H]+; HR-TOF-MS m/z 478.2603 [M + H]+ (calcd. for 
C29H36NO5, 478.2588).  
3.8. Antibiotic Activities Assays 
The antimicrobial activities of compounds 1 and 2 against the bacteria Bacillus subtilis (DSM 347), 
the plant pathogen Xanthomonas campestris (DSM 2405), as well as the human pathogenic yeast 
Candida albicans (DSM 1386) were determined according to Ohlendorf et al. [28]. Escherichia coli 
K12 (DSM 498) and Pseudomonas aeruginosa (DSM 50071) were used in the same manner as  
B. subtilis. The bioassays with the clinically relevant bacterial strains Staphylococcus epidermidis  
(DSM 20044), methicillin-resistant Staphylococcus aureus (MRSA) (DSM 18827), and the causative 
agent of acne, Propionibacterium acnes (DSM 1897T), were performed as described by Silber et al. [29]. 
Staphylococcus aureus (DSM 346) was investigated in the same manner as S. epidermidis. The 
phytopathogenic fungus Septoria tritici was tested according to Jansen et al. [30].  
4. Conclusions 
Only little information is available on the production of secondary metabolites by members of the 
fungal order Pleosporales. The isolate Nodulisporium sp. CRIF2 from an unidentified soft coral  
(Surin Island, Thailand) produced the new compounds (Z)-6-benzylidene-3-hydroxy-methyl-1,4-
dimethyl-3-methylsulfanylpiperazine-2,5-dione, which exhibited weak cytotoxic activity, and (3S,3′R)-
3-(3′-hydroxybutyl)-7-methoxyphtalide, as well as the known substances (S)-3-butyl-7-methoxyphtalide, 
(3R,6R)-bisdethiodi(methylthio)-hyalodendrin, and bis-N-norgliovictin [31]. Nodulisporacid A, and 
derivatives thereof, and the tetramic acid vermelhotin were shown to be produced by the Pleosporales 
strain CRI247-01, which was derived from an unidentified sponge [32]. Nodulisporacid A and 
vermelhotin inhibited Plasmodium falciparum, the causative agents of malaria tropica.  
Xanthoquinodine A3 and B3 were produced by Humicola sp. and showed anticoccidial (A3 and B3) 
and antibacterial (A3) activity [33]. Antimycobacterial properties were exhibited by chaetomanone, a 
product from Chaetomium globosum [34]. In addition, some metabolites with unknown bioactivities 
were described: Paecilin A from a mangrove derived Paecilomyces sp. strain, the pigment ergoxanthin 
from Claviceps purpurea, and the ergochromes blennolide D and G from Blennoria sp. [35–37].  
Polyketides 1 and 2 were shown to contain two distinct domains, a bicyclic hydrocarbon and a 
tetramic acid, connected by a bridging carbonyl. The tetramic acid substructure of compound 1 was 
proved to possess a unique 5-benzylpyrrolidine-2,4-dione unit. Both compounds, lindgomycin (1) and 
ascosetin (2), showed promising antibiotic inhibitory activities against clinically relevant microorganisms, 
in particular Gram-positive bacteria, yeasts, and fungi, such as methicillin-resistant S. aureus (MRSA), 
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P. acnes, S. tritici, and C. albicans. The lack of activity against Gram-negative bacteria has already been 
noticed for other tetramic acid derivatives by Lowery et al. [38] and maybe related to the difference in 
the cell wall structures. Apparently the outer membrane of Gram-negative bacteria is an efficient 
permeability barrier for these molecules. 
The WHO stated that 25,000 persons die each year due to infections with antibiotic resistant bacteria 
in 29 European countries [39]. Specifically, MRSA strains are causing infections with high mortality 
rates and a growing rate of resistance [40]. According to the data raised by the European Antimicrobial 
Resistance Surveillance Network (EARS-Net), the percentage of MRSA-positive isolates exceed 20% in 
11 of 28 European countries that participate at the EARS-Net [41]. In addition to the highly demanded 
search for new natural products active against antibiotic-resistant bacteria, a number of other health 
issues also require new active compounds for improved treatment. These include new molecules against 
the human pathogens P. acnes or C. albicans. P. acnes is involved in the inflammatory skin disease acne 
vulgaris and causes opportunistic human infections [42]. Candida species are responsible for the 
infectious disease candidiasis, especially in immuno-compromised patients [43]. More than 90% of 
invasive infections are caused by C. albicans. Without a doubt, there still remains a strong demand for 
new antibiotics that might be more effective, less toxic, and show a lower risk of resistance. Lindgomycin 
(1) as well as ascosetin (2) could be promising candidates in this search. 
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